Table 1

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic

Item No

Checklist item

Reported on page No


Title and abstract

1a

Identification as a randomised trial in the title

1b

Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts [21,31])

Introduction

Background and objectives

2a

Scientific background and explanation of rationale

2b

Specific objectives or hypotheses

Methods

Trial design

3a

Description of trial design (such as parallel, factorial) including allocation ratio

3b

Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Participants

4a

Eligibility criteria for participants

4b

Settings and locations where the data were collected

Interventions

5

The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

Outcomes

6a

Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

6b

Any changes to trial outcomes after the trial commenced, with reasons

Sample size

7a

How sample size was determined

7b

When applicable, explanation of any interim analyses and stopping guidelines

Randomisation:

Sequence generation

8a

Method used to generate the random allocation sequence

8b

Type of randomisation; details of any restriction (such as blocking and block size)

Allocation concealment mechanism

9

Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Implementation

10

Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Blinding

11a

If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

11b

If relevant, description of the similarity of interventions

Statistical methods

12a

Statistical methods used to compare groups for primary and secondary outcomes

12b

Methods for additional analyses, such as subgroup analyses and adjusted analyses

Results

Participant flow (a diagram is strongly recommended)

13a

For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

13b

For each group, losses and exclusions after randomisation, together with reasons

Recruitment

14a

Dates defining the periods of recruitment and follow-up

14b

Why the trial ended or was stopped

Baseline data

15

A table showing baseline demographic and clinical characteristics for each group

Numbers analysed

16

For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

Outcomes and estimation

17a

For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

17b

For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Ancillary analyses

18

Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Harms

19

All important harms or unintended effects in each group (for specific guidance see CONSORT for harms [28])

Discussion

Limitations

20

Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

Generalisability

21

Generalisability (external validity, applicability) of the trial findings

Interpretation

22

Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

Other information

Registration

23

Registration number and name of trial registry

Protocol

24

Where the full trial protocol can be accessed, if available

Funding

25

Sources of funding and other support (such as supply of drugs), role of funders


*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration [13] for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials [11], non-inferiority and equivalence trials [12], non-pharmacological treatments [32], herbal interventions [33], and pragmatic trials [34]. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see http://www.consort-statement.org webcite.

Schulz et al. BMC Medicine 2010 8:18   doi:10.1186/1741-7015-8-18

Open Data